Participation in clinical trials has demonstrable effects on improved outcomes - they show us what works (and what doesn’t) in medicine. While fewer than 1 in 20 adult cancer patients in the U.S. have participated in a clinical trial, 60% of childhood cancer patients have participated. This is one key reason that survival rates for childhood cancer have increased so dramatically in the last few decades. Advances in medicine are made possible due in large part to the people who volunteer as participants in clinical trials, and the researchers and clinicians who run them! With around 25% of all active clinical trials in the U.S. having a site in California, people in the Golden State are making an extraordinary contribution to advancing human health.

Facts About Clinical Trials

About 50% of clinical trials in California are funded solely by life sciences companies.

Clinical trials in California are generating a large amount of data critical for advancing research in the most challenging diseases.

- Over 25% of cancer clinical trials in the U.S. have a trial site in California
- 1/3 of rare disease clinical trials in the U.S. have a trial site in California
- 1/3 of HIV clinical trials in the U.S. have a trial site in California

Clinical Trials Funding Sources

Almost half of all clinical trials in California are funded solely by life sciences companies. Over 25% of trials in California receive funding from some combination of industry, NIH, non-NIH U.S. Federal agencies and some combinations of multiple other sources. More than 68% of clinical trials in California receiving funding from the NIH also receive funding from additional non-industry sources.

Patients in California are fortunate to live in a state that’s home to nearly one quarter of all North American clinical trials. Public and private financial support for clinical research are all critical to supporting and expanding the number and reach of clinical trials in California, however, private industry is still the single largest funder of clinical trials in the Golden State and across the U.S. Let’s protect this ecosystem of bold biomedical innovation, so that patients can continue to benefit from the clinical trials and R&D coming out of California.